Executive Order 13887: Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health
President: Donald J. Trump
Set an interagency effort to improve influenza-vaccine research, production capacity and distribution planning, with agency recommendations under existing law.
Status: In effect. Sources: Official source · Official source.
Is Executive Order 13887 still in effect? Yes. Executive Order 13887 of September 19, 2019 remains unrevoked. Section 5 sets no automatic expiration for its vaccine task force, and CDC continues to identify itself as a member. The five-year reporting schedule did not itself terminate the order's influenza-vaccine modernization directions.
What does Executive Order 13887 do?
EO 13887 asked HHS and other agencies to modernize influenza-vaccine production, reduce reliance on egg-based methods and strengthen domestic preparedness, subject to public-health law and appropriations.
Later evidence reviewed September 24, 2026: HHS published a National Influenza Vaccine Modernization Strategy for 2020–2030 expressly directed by EO 13887. The strategy is a planning outcome, not proof of completed vaccine capacity. HHS influenza vaccine strategy.
Before and after
Before the order
Federal agencies used existing influenza vaccine development and procurement programs.
After the order
HHS published a National Influenza Vaccine Modernization Strategy for 2020–2030 expressly directed by EO 13887. The strategy is a planning outcome, not proof of completed vaccine capacity.
Who had to do what
| Agency / official | What the signed order directed | Deadline / timing |
|---|---|---|
| National Influenza Vaccine Task Force | Identify and monitor actions to modernize influenza vaccines and increase vaccination; report recommendations and a five-year national plan to the President through the National Security and Domestic Policy assistants, OMB, and OSTP. | Initial report within 120 days; updates by June 1 each year for the next five years. |
| Secretary of Defense | Co-chair the Task Force with HHS. Provide OMB procurement-transition costs; direct vaccine-effectiveness epidemiology with VA/CDC/HHS and clinical studies at Defense sites; identify early and late vaccine-development opportunities with HHS; investigate immunity correlates; assess Defense manufacturing-facility feasibility; accelerate scalable antibody prophylaxis research with HHS. | Task Force report within 120 days; annual updates by June 1 for five years. No separate section 4 completion deadline. |
| Secretary of Health and Human Services | Co-chair the Task Force with Defense and oversee the assigned work of ASPR/BARDA, NIH, FDA, CDC, and CMS. Support adjuvant clinical studies with Defense, NIH, and VA. | Task Force report within 120 days; annual updates by June 1 for five years. No separate section 4 completion deadline. |
| Assistant Secretary for Preparedness and Response / BARDA | Estimate costs of cell-based/recombinant manufacturing expansion through private cost-sharing with pandemic pricing, adjuvant production, fill-and-finish capacity, and delivery systems addressing needle/syringe limits. Evaluate manufacturer incentives, partnerships, and pre-pandemic technology transfer; support adjuvant studies with Defense/NIH/VA; update production research priorities. | No fixed deadline stated. |
| NIH Director | Provide the Task Force an estimated timeline for developing universal influenza vaccines and support coordinated adjuvant clinical studies. | No fixed deadline stated. |
| FDA Commissioner | Implement production-process improvements reducing production time; with CDC propose strain-selection timing alternatives; support cell-line/expression-system research with Defense/BARDA/CDC; assess advanced-manufacturing platforms with BARDA and manufacturers. | No fixed deadline stated. |
| CDC Director | Expand comparative vaccine-effectiveness studies; explore cell-based candidate production capacity; plan whole-genome characterization capacity; increase uptake through communication and removal of barriers; inform providers about vaccine performance; coordinate strain timing and cell-line work. | No fixed deadline stated. |
| CMS Administrator | Examine payment, legal, regulatory, and policy approaches that could improve adoption of domestically produced, pandemic-ready influenza vaccines. | No fixed deadline stated. |
| Secretary of Veterans Affairs | Provide OMB vaccine procurement-transition costs; participate in Defense-led epidemiologic vaccine-effectiveness studies and coordinated adjuvant studies. | No fixed deadline stated. |
Source: Signed Federal Register text.
What happened next
EO 13887 signed; its Federal Register publication followed.
Legal and source detail
How it works legally
The Federal Register record identifies EO 13887, its title and signing date. HHS published a National Influenza Vaccine Modernization Strategy for 2020–2030 expressly directed by EO 13887. The strategy is a planning outcome, not proof of completed vaccine capacity. The linked source supports this particular later event; it does not establish every present legal or operational effect.
Sources by type
If a source is unavailable, first check the cited publisher or another official repository. The cited publisher remains the authority.
Primary and official sources
Orders, laws, court records and official implementation material.
- HHS influenza vaccine strategy (opens in a new tab) Official record
How we checked this
Last checked against the sources above on September 24, 2026. How we research →